Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100932
Status:
COMPLETED
Last Update Posted:
2012-03-27
First Post:
2005-01-07
Brief Title:
Phase II Study Of E7389 Halichondrin B Analogue In Patients With Advanced Non-Small Cell Lung Cancer NSCLC Who Progressed During Or After Platinum-Based Doublet Chemotherapy
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
Phase II Study of E7389 a Halichondrin B Analog in Patients With Advanced Non-Small Cell Lung Cancer NSCLC Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of E7389 in patients with recurrent andor metastatic Non-Small-Cell Lung Cancer NSCLC who progressed during or after treatment with a platinum agent and another chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None